Becton Dickinson and Co (NYSE:BDX) Given Consensus Rating of “Buy” by Brokerages

Becton Dickinson and Co (NYSE:BDX) has received a consensus rating of “Buy” from the thirteen brokerages that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $266.40.

BDX has been the subject of several research reports. Piper Jaffray Companies decreased their price target on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Morgan Stanley raised their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. BMO Capital Markets decreased their price target on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a report on Friday, May 10th. KeyCorp restated an “overweight” rating and set a $262.00 price target (down from $273.00) on shares of Becton Dickinson and in a report on Friday, May 10th. Finally, UBS Group decreased their price target on shares of Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, May 10th.

In other Becton Dickinson and news, EVP Roland Goette sold 1,717 shares of Becton Dickinson and stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $249.88, for a total value of $429,043.96. Following the completion of the sale, the executive vice president now directly owns 19,966 shares in the company, valued at $4,989,104.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James C. Lim sold 1,929 shares of Becton Dickinson and stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $252.01, for a total transaction of $486,127.29. The disclosure for this sale can be found here. Insiders sold 24,529 shares of company stock valued at $5,836,116 over the last quarter. Corporate insiders own 0.12% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Duality Advisers LP raised its position in shares of Becton Dickinson and by 12.7% in the first quarter. Duality Advisers LP now owns 17,480 shares of the medical instruments supplier’s stock valued at $4,365,000 after purchasing an additional 1,970 shares during the period. Meridian Wealth Advisors LLC increased its position in Becton Dickinson and by 2.7% during the first quarter. Meridian Wealth Advisors LLC now owns 3,787 shares of the medical instruments supplier’s stock worth $946,000 after acquiring an additional 99 shares during the period. Pratt Collard Advisory Partners LLC increased its position in Becton Dickinson and by 5.1% during the first quarter. Pratt Collard Advisory Partners LLC now owns 2,078 shares of the medical instruments supplier’s stock worth $519,000 after acquiring an additional 100 shares during the period. Investec Asset Management North America Inc. increased its position in Becton Dickinson and by 5.1% during the first quarter. Investec Asset Management North America Inc. now owns 11,123 shares of the medical instruments supplier’s stock worth $2,778,000 after acquiring an additional 543 shares during the period. Finally, Black Diamond Financial LLC bought a new position in Becton Dickinson and during the second quarter worth $562,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Shares of Becton Dickinson and stock traded up $1.98 during trading hours on Tuesday, hitting $248.33. The company’s stock had a trading volume of 761,400 shares, compared to its average volume of 1,114,327. The business has a 50 day moving average price of $251.88 and a two-hundred day moving average price of $244.28. Becton Dickinson and has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a market cap of $66.50 billion, a PE ratio of 22.55, a PEG ratio of 1.79 and a beta of 1.11. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.05 by $0.03. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The business had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same period in the previous year, the business earned $2.91 earnings per share. The business’s revenue was up 1.7% on a year-over-year basis. As a group, research analysts anticipate that Becton Dickinson and will post 11.68 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Fundamental Analysis and Choosing Stocks

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.